Funded Tech Companies
Radionetics Oncology
Operating out of Menlo Park, Radionetics Oncology has funding from GordonMD Global Investments, Frazier Life Sciences and 5AM Ventures.
Company Overview
Company Name
Radionetics Oncology
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
70 Willow Road 200
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Website
Email Address
Company Background Information
Overview
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
1/3/2024
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Grayson
Chief Medical Officer
Istvan Molnar
Company Investors
Browse more funded tech companies:
Radiomer Therapeutics | RadioRx
Share this article
About Our VC & M&A Database
Our data comes from VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs